EP0991754A2 - Proteases from gram-positive organisms - Google Patents

Proteases from gram-positive organisms

Info

Publication number
EP0991754A2
EP0991754A2 EP98935681A EP98935681A EP0991754A2 EP 0991754 A2 EP0991754 A2 EP 0991754A2 EP 98935681 A EP98935681 A EP 98935681A EP 98935681 A EP98935681 A EP 98935681A EP 0991754 A2 EP0991754 A2 EP 0991754A2
Authority
EP
European Patent Office
Prior art keywords
serine protease
gram
host cell
bacillus
microorganism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP98935681A
Other languages
German (de)
English (en)
French (fr)
Inventor
David A. Estell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Danisco US Inc
Original Assignee
Genencor International BV
Genencor International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genencor International BV, Genencor International Inc filed Critical Genencor International BV
Priority to EP98935681A priority Critical patent/EP0991754A2/en
Publication of EP0991754A2 publication Critical patent/EP0991754A2/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/38Products with no well-defined composition, e.g. natural products
    • C11D3/386Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38663Stabilised liquid enzyme compositions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18Carboxylic ester hydrolases (3.1.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)

Definitions

  • the present invention relates to serine proteases derived from gram-positive microorganisms
  • the present invention provides nucleic acid and ammo acid sequences of serine protease 1 , 2, 3, 4 and 5 identified in Bacillus
  • the present invention also provides methods for the production of serine protease 1 , 2, 3, 4 and 5 in host cells as well as the production of heterologous proteins in a host cell having a mutation or deletion of part or all of at least one of the serine proteases of the present invention
  • Gram-positive microorganisms such as members of the group Bacillus
  • Gram-positive bacteria have been used for large-scale industrial fermentation due, in part, to their ability to secrete their fermentation products into the culture media
  • secreted proteins are exported across a cell membrane and a cell wall, and then are subsequently released into the external media usually maintaining their native conformation
  • proteases are produced in large quantities for industrial purposes.
  • a negative aspect of the presence of proteases in gram-positive organisms is their contribution to the overall degradation of secreted heterologous or foreign proteins
  • proteases found in microorganisms are based on their catalytic mechanism which results in four groups the serine proteases, metalloproteases, cysteine proteases, and aspartic proteases These categories can be distinguished by their sensitivity to various inhibitors
  • the serine proteases are inhibited by phenylmethylsulfonylfluo ⁇ de (PMSF) and dnsopropylfluorophosphate (DIFP), the metalloproteases by chelating agents, the cysteine enzymes by lodoacetamide and heavy metals and the aspartic proteases by pepstatin
  • the serine proteases have alkaline pH optima
  • the metalloproteases are optimally active around neutrality
  • the cysteine and aspartic enzymes have acidic pH optima (Biotechnology Handbooks, Bacillus vol 2, edited by Harwood, 1989 Plenum Press, New York)
  • serine proteases Proteolytic enzymes that are dependent upon a serine residue for catalytic activity are called serine proteases As described in Methods in Enzymology, vol 244, Academic Press, Inc 1994, page 21 , serine proteases of the family S9 have the catalytic residue triad "Ser-Asp-His with conservation of ammo acids around them SUMMARY OF THE INVENTION
  • the present invention relates to the unexpected discovery of five heretofore unknown or unrecognized S9 type serine proteases found in uncharacte ⁇ zed translated genomic nucleic acid sequences of Bacillus subtilis, designated herein as SP1 , SP2, SP3, SP4 and SP5 having the nucleic acid and ammo acid as shown in the Figures
  • the present invention is based, in part, upon the presence the ammo acid triad S-D-H in the five serine proteases, as well as ammo acid conservation around the triad
  • the present invention is also based in part upon the heretofore uncharacte ⁇ zed or unrecognized overall ammo acid relatedness that SP1 , SP2, SP3, SP4 and SP5 have with the serine protease dipeptidyl- ammo peptidase B from yeast (DAP) and with each other
  • the present invention provides isolated polynucleotide and ammo acid sequences for SP1 , SP2, SP3, SP4 and SP5 Due to the degeneracy of the genetic code, the present invention encompasses any nucleic acid sequence that encodes the SP1 , SP2, SP3, SP4 and SP5 deduced ammo acid sequences shown in Figures 2A-2B-F ⁇ gure 6, respectively
  • the present invention encompasses ammo acid variations of B subtilis SP1 , SP2, SP3, SP4 and SP5 disclosed herein that have proteolytic activity B subtilis SP1 , SP2, SP3, SP4 and SP5, as well as proteolytically active ammo acid variations thereof, have application in cleaning compositions
  • SP1 , SP2, SP3, SP4 and SP5 obtainable from a gram-positive microorganism are produced on an industrial fermentation scale in a microbial host expression system
  • isolated and purified SP1 , SP2, SP3, SP4 or SP5 obtainable from a gram-positive microorganism is used in compositions of matter intended for cleaning purposes, such as detergents
  • the present invention provides a cleaning composition comprising at least one of SP1 , SP2, SP3, SP4 and SP5 obtainable from a gram-positive microorganism
  • the serine protease may be used alone in the cleaning composition or in combination with other enzymes and/or mediators or enhancers
  • the present invention also encompasses gram-positive microorganism having a mutation or deletion of part or all of the gene encoding SP1 , SP2, SP3, SP4 and/or SP5, which results in the mactivation of their proteolytic activity, either alone or in combination with deletions or mutations in other proteases, such as apr, npr, epr, mpr for example, or other proteases known to those of skill in the art
  • the gram-positive organism is a member of the genus Bacillus
  • the Bacillus is Bacillus subtilis
  • the gram-positive microorganism host having one or more deletions or mutations in a serine protease of the present invention is further genetically engineered to produce a desired protein.
  • the desired protein is heterologous to the gram-positive host cell.
  • the desired protein is homologous to the host cell.
  • the present invention encompasses a gram- positive host cell having a deletion or interruption of the naturally occurring nucleic acid encoding the homologous protein, such as a protease, and having nucleic acid encoding the homologous protein or a variant thereof re-introduced in a recombinant form.
  • the host cell produces the homologous protein.
  • the present invention also provides methods and expression systems for reducing degradation of heterologous or homologous proteins produced in gram-positive microorganisms comprising the steps of obtaining a Bacillus host cell comprising nucleic acid encoding said heterologous protein wherein said host cell contains a mutation or deletion in at least one of the genes encoding SP1 , SP2, SP3, SP4 and SP5; and growing said Bacillus host cell under conditions suitable for the expression of said heterologous protein.
  • the gram-positive microorganism may be normally sporulating or non-sporulating.
  • the present invention provides methods for detecting gram positive microorganism homologs of B. subtilis SP1 , SP2, SP3, SP4 and SP5 that comprises hybridizing part or all of the nucleic acid encoding B. subtilis SP1, SP2, SP3, SP4 and SP5 with nucleic acid derived from gram-positive organisms, either of genomic or cDNA origin.
  • Figures 1A-1C shows the DNA (SEQ ID NO:1) and deduced amino acid sequence (SEQ ID NO:2) for SP1 (YUXL).
  • Figure 2A-2B show an amino acid alignment between DAP (dap2_yeast) (SEQ ID NO:3) and SP1 (YUXL).
  • DAP dap2_yeast
  • SP1 YUXL
  • Figure 3 shows an amino acid alignment between SP1 (YUXL) (SEQ ID NO:2) and SP2 (YTMA) (SEQ ID NO:5).
  • Figure 4 shows and amino acid alignment between SP1 (YUXL) (SEQ ID NO:2) and SP3 (YITV) (SEQ ID NO:7).
  • Figure 5 shows and amino acid alignment between SP1 (YUXL) (SEQ ID NO:2) and SP4 (YQKD) (SEQ ID NO:9).
  • Figure 6 shows and amino acid alignment between SP1 (YUXL) (SEQ ID NO:2) and SP5 (CAH) (SEQ ID NO: 10).
  • Figures 7A-7B shows the DNA (SEQ ID NO:4) and deduced amino acid sequence for SP2 (YTMA) (SEQ ID NO:5).
  • Figures 8A-8B shows the DNA (SEQ ID NO:6) and deduced amino acid sequence for SP3 (YITV) (SEQ ID NO:7).
  • Figures 9A-9B shows the DNA (SEQ ID NO:8) and deduced amino acid sequence for SP4 (YQKD) (SEQ ID NO:9).
  • Bacillus includes all members known to those of skill in the art, including but not limited to B. subtilis, B. licheniformis, B. lentus, B. brevis, B. ' stearothermophilus, B. alkalophilus, B. amyloliquefaciens, B. coagulans, B. ciculans, B. lautus and B. thu ⁇ ngiensis.
  • subtilis SP1 (YuxL) refers to the DNA and deduced am o acid sequence shown in Figures 1A-1C and Figures 2A-2B
  • SP2 (YtmA) refers to the DNA and deduced am o acid sequence shown in Figures 7A-7B and Figure 3
  • SP3 (YitV) refers to the DNA and deduced am o acid sequence shown in Figures 8A-8B and Figure 4
  • SP4 (YqkD) refers to the DNA and deduced ammo acid sequence shown in Figures 9A-9B and Figure 5
  • SP5 (CAH) refers to the deduced ammo acid sequence shown in Figure 6
  • the present invention encompasses ammo acid variations of the
  • nucleic acid refers to a nucleotide or polynucleotide sequence, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic origin which may be double-stranded or single-stranded, whether representing the sense or antisense strand
  • amino acid refers to peptide or protein sequences or portions thereof
  • polynucleotide homolog refers to a novel gram-positive microorganism polynucleotide that has at least 80%, at least 90% and at least 95% identity to B subtilis SP1, SP2, SP3, SP4 or SP5, or which is capable of hybridizing to B subtilis SP1 , SP2, SP3, SP4 or SP5 under conditions of high stringency and which encodes an ammo acid sequence having serine protease activity
  • isolated or “purified” as used herein refer to a nucleic acid or ammo acid that is removed from at least one component with which it is naturally associated
  • heterologous protein refers to a protein or polypeptide that does not naturally occur in a gram-positive host cell
  • heterologous proteins include enzymes such as hydrolases including proteases, cellulases, amylases, carbohydrases, and lipases, isomerases such as racemases, epimerases, tautomerases, or mutases, transferases, kmases and phophatases
  • the heterologous gene may encode therapeutically significant proteins or peptides, such as growth factors, cytokines, ligands, receptors and inhibitors, as well as vaccines and antibodies
  • the gene may encode commercially important industrial proteins or peptides, such as proteases, carbohydrases such as amylases and glucoamylases, cellulases, oxidases and lipases
  • the gene of interest may be a naturally occurring gene, a mutated gene or a synthetic gene
  • homologous protein refers to a protein or polypeptide native or naturally occurring in a gram-positive host cell
  • the invention includes host cells producing the homologous protein via recombinant DNA technology
  • the present invention encompasses a gram-positive host cell having a deletion or interruption of the nucleic acid encoding the naturally occurring homologous protein, such as a protease, and having nucleic acid encoding the homologous protein, or a variant thereof re-introduced in a recombinant form
  • the host cell produces the homologous protein
  • the term "overexpressmg" when referring to the production of a protein in a host cell means that the protein is produced in greater amounts than its production in its naturally occurring environment
  • proteolytic activity refers to a protein that is able to hydrolyze a peptide bond
  • Enzymes having proteolytic activity are described in Enzyme Nomenclature, 1992, edited Webb Academic Press, Inc.
  • the host cell is a gram-positive host cell that has a deletion or mutation in the naturally occurring serine protease said mutation resulting in the complete deletion or mactivation of the production by the host cell of the proteolytic serine protease gene product
  • the host cell is additionally genetically engineered to produced a desired protein or polypeptide
  • host cells may also be desired to genetically engineer host cells of any type to produce a gram-positive senne protease SP1 , SP2, SP3, SP4 or SP5
  • host cells are used in large scale fermentation to produce large quantities of the serine protease which may be isolated or purified and used in cleaning products, such as detergents
  • the SP1 , SP2, SP3 and SP4 polynucleotides having the sequences as shown in the Figures encode the Bacillus subtilis serine SP1 , SP2, SP3, and SP4
  • a variety of polynucleotides can encode the Bacillus SP1 , SP2, SP3, SP4 and SP5
  • the present invention encompasses all such polynucleotides
  • the present invention encompasses novel SP1 , SP2, SP3, SP4 and SP5 polynucleotide homologs encoding gram-positive microorganism serine proteases SP1 , SP2, SP3, SP4 and SP5, respectively, which have at least 80%, or at least 90% or at least 95% identity to ⁇ subtilis as long as the homolog encodes a protein that has proteolytic activity Gram-positive polynucleotide homologs of B subtilis SP1 , SP2, SP3, SP4 or SP5 may be obtained by standard procedures known in the art from, for example, cloned DNA (e g , a DNA "library”), genomic DNA libraries, by chemical synthesis once identified, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from a desired cell (See, for example, Sambrook et al , 1989, Molecular Cloning, A Laboratory Manual, 2d Ed , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, Glover,
  • DNA fragments are generated, some of which will encode the desired gene
  • the DNA may be cleaved at specific sites using various restriction enzymes Alternatively, one may use DNAse in the presence of manganese to fragment the DNA, or the DNA can be physically sheared, as for example, by sonication
  • linear DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography
  • identification of the specific DNA fragment containing the SP1 , SP2, SP3, SP4 or SP5 may be accomplished in a number of ways
  • a B subtilis SP1 , SP2, SP3, SP4 or SP5 gene of the present invention or its specific RNA, or a fragment thereof, such as a probe or primer may be isolated and labeled and then used in hybridization assays to detect a gram-positive SP1 , SP2, SP3, SP4 or SP5 gene (Benton, W and Davis, R , 1977, Science 196 180, Grunstein, M And Hogness, D ,
  • the present invention provides a method for the detection of gram- positive SP1 , SP2, SP3, SP4 or SP5 polynucleotide homologs which comprises hybridizing part or all of a nucleic acid sequence of B subtilis SP1 SP2, SP3, SP4 or SP5 with gram- positive microorganism nucleic acid of either genomic or cDNA origin
  • gram-positive microorganism polynucleotide sequences that are capable of hybridizing to the nucleotide sequence of B subtilis SP1 , SP2, SP3, SP4 or SP5 under conditions of intermediate to maximal stringency Hybridization conditions are based on the melting temperature (Tm) of the nucleic acid binding complex, as taught in Berger and Kimmel (1987, Guide to Molecular
  • Maximum stringency typically occurs at about Tm-5°C (5°C below the Tm of the probe), “high stringency” at about 5°C to 10°C below Tm, “intermediate stringency” at about 10°C to 20°C below Tm, and “low stringency” at about 20°C to 25°C below Tm
  • a maximum stringency hybridization can be used to identify or detect identical polynucleotide sequences while an intermediate or low stringency hybridization can be used to identify or detect polynucleotide sequence homologs
  • hybridization shall include "the process by which a strand of nucleic acid joins with a complementary strand through base pairing" (Coombs J (1994) Dictionary of Biotechnology, Stockton Press, New York NY)
  • PCR polymerase chain reaction
  • B subtilis ammo acid sequences SP1 SP2, SP3, SP4 and SP5 were identified via a FASTA search of Bacillus subtilis genomic nucleic acid sequences B subtilis SP1 (YuxL) was identified by its structural homology to the serine protease DAP classified as an S9 type serine protease, designated in Figures 2A-2B as "dap2_yeast" As shown in Figures 2A-2B, SP1 has the ammo acid dyad "S-D-H" indicated Conservation of ammo acids around each residue is noted in Figures 2A-2B through Figure 6 SP2 (YtmA), SP3 (YitV), SP4 (YqkD) and SP5 (CAH) were identified upon by their structural and overall ammo acid homology to SP1 (YuxL) SP1 and SP4 were described in Parsot and Kebayashi, respectively, but were not characterized as serine proteases or serine proteases
  • the present invention provides host cells, expression methods and systems for the enhanced production and secretion of desired heterologous or homologous proteins in gram-positive microorganisms
  • a host cell is genetically engineered to have a deletion or mutation in the gene encoding a gram-positive SP1 , SP2, SP3, SP4 or SP5 such that the respective activity is deleted
  • a gram-positive microorganism is genetically engineered to produce a serine protease of the present invention Inactivation of a gram-positive serine protease in a host cell
  • the mutation is a non- reverting mutation
  • One method for mutating nucleic acid encoding a gram-positive serine protease is to clone the nucleic acid or part thereof, modify the nucleic acid by site directed mutagenesis and reintroduce the mutated nucleic acid into the cell on a plasmid
  • the mutated gene may be introduced into the chromosome In the parent host cell, the result is that the naturally occurring nucleic acid and the mutated nucleic acid are located in tandem on the chromosome
  • the modified sequence is left in the chromosome having thereby effectively introduced the mutation into the chromosomal gene for progeny of the parent host cell
  • Another method for inactivating the serine protease proteolytic activity is through deleting the chromosomal gene copy
  • the entire gene is deleted, the deletion occurring in such as way as to make reversion impossible
  • a partial deletion is produced, provided that the nucleic acid sequence left in the chromosome is too short for homologous recombination with a plasmid encoded serine protease gene
  • nucleic acid encoding the catalytic ammo acid residues are deleted
  • Deletion of the naturally occurring gram-positive microorganism serine protease can be carried out as follows A serine protease gene including its 5 and 3' regions is isolated and inserted into a cloning vector The coding region of the serine protease gene is deleted form the vector in vitro, leaving behind a sufficient amount of the 5' and 3' flanking sequences to provide for homologous recombination with the naturally occurring gene in the parent host cell The vector is then transformed into the gram-positive host cell The vector integrates into the chromosome via homologous recombination in the flanking regions This method leads to a gram-positive strain in which the protease gene has been deleted
  • the vector used in an integration method is preferably a plasmid
  • a selectable marker may be included to allow for ease of identification of desired recombinant microorgansims
  • the vector is preferably one which can be selectively integrated into the chromosome This can be achieved by introducing an inducible origin of replication, for example, a temperature sensitive origin into the plasmid
  • an inducible origin of replication for example, a temperature sensitive origin
  • the replication function of the plasmid is inactivated, thereby providing a means for selection of chromosomal integrants Integrants may be selected for growth at high temperatures in the presence of the selectable marker, such as an antibiotic Integration mechanisms are described in WO 88/06623
  • Another method of inactivating the naturally occurring serine protease gene is to mutagenize the chromosomal gene copy by transforming a gram-positive microorganism with oligonucleotides which are mutagenic Alternatively, the chromosomal serine protease gene can be replaced with a mutant gene by homologous recombination
  • the present invention encompasses host cells having additional protease deletions or mutations, such as deletions or mutations in apr, npr, epr, mpr and others known to those of skill in the art
  • United States Patent 5 264,366 discloses Bacillus host cells having a deletion of apr and npr
  • United States Patent 5,585,253 discloses Bacillus host cells having a deletion of epr, Margot et al , 1996
  • Microbiology 142 3437-3444 disclose host cells having a deletion in wpr
  • EP patent 0369817 discloses Bacillus host cells having a deletion of mpr
  • an expression vector comprising at least one copy of nucleic acid encoding a gram-positive microorganism SP1 , SP2, SP3, SP4 or SP5, and preferably comprising multiple copies is transformed into the host cell under conditions suitable for expression of the serine protease
  • polynucleotides which encode a gram-positive microorganism SP1 , SP2, SP3, SP4 or SP5, or fragments thereof, or fusion proteins or polynucleotide homolog sequences that encode ammo acid variants of B SP1 , SP2, SP3, SP4 or SP5 may be used to generate recombinant DNA molecules that direct their expression in host cells
  • the gram-positive host cell belongs to the genus Bacillus
  • the gram positive host cell is B subtilis
  • RNA transcripts possessing non-naturally occurring codons Codons preferred by a particular gram-positive host cell (Murray E et al (1989) Nuc Acids Res 17 477-508) can be selected, for example, to increase the rate of expression or to produce recombinant RNA transcripts having desirable properties, such as a longer half-life, than transcripts produced from naturally occurring sequence Altered SP1 , SP2, SP3, SP4 or SP5 polynucleotide sequences which may be used in accordance with the invention include deletions, insertions or substitutions of different nucleotide residues resulting in a polynucleotide that encodes the same or a functionally equivalent SP1 , SP2, SP3, SP4 or SP5 homolog, respectively
  • a "deletion" is defined as a change in either nucleotide or ammo acid sequence in which one or more nucleotides or am
  • an "insertion” or “addition” is that change in a nucleotide or ammo acid sequence which has resulted in the addition of one or more nucleotides or ammo acid residues, respectively, as compared to the naturally occurring SP1 , SP2, SP3, SP4 or SP5
  • substitution results from the replacement of one or more nucleotides or ammo acids by different nucleotides or am o acids, respectively
  • the encoded protein may also show deletions, insertions or substitutions of am o acid residues which produce a silent change and result in a functionally SP1 , SP2, SP3, SP4 or SP5 variant
  • Deliberate ammo acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the variant retains the ability to modulate secretion
  • negatively charged am o acids include aspartic acid and glutamic acid
  • positively charged ammo acids include lysine and argmine
  • ammo acids with uncharged polar head groups having similar hydrophilicity values include leucme, isoleucine, vahne, glycine, alanme, asparagme, glutamine, serine, threonme, phenylalanme, and tyrosme
  • the SP1 , SP2 SP3, SP4 or SP5 polynucleotides of the present invention may be engineered in order to modify the cloning, processing and/or expression of the gene product
  • mutations may be introduced using techniques which are well known in the art, eg, site-directed mutagenesis to insert new restriction sites, to alter glycosylation patterns or to change codon preference, for example
  • a gram-positive microorganism SP1 , SP2, SP3, SP4 or SP5 polynucleotide may be ligated to a heterologous sequence to encode a fusion protein
  • a fusion protein may also be engineered to contain a cleavage site located between the serine protease nucleotide sequence and the heterologous protein sequence, so that the serine protease may be cleaved and purified away from the heterologous moiety
  • Expression vectors used in expressing the serine proteases of the present invention in gram-positive microorganisms comprise at least one promoter associated with a serine protease selected from the group consisting of SP1 , SP2, SP3, SP4 and SP5, which promoter is functional in the host cell
  • the promoter is the wild-type promoter for the selected serine protease and in another embodiment of the present invention, the promoter is heterologous to the serine protease, but still functional in the host cell
  • nucleic acid encoding the serine protease is stably integrated into the microorganism genome
  • the expression vector contains a multiple cloning site cassette which preferably comprises at least one restriction endonuclease site unique to the vector, to facilitate ease of nucleic acid manipulation
  • the vector also comprises one or more selectable markers
  • selectable marker refers to a gene capable of expression in the gram-positive host which allows for ease of selection of those hosts containing the vector Examples of such selectable markers include but are not limited to antibiotics, such as, erythromycin, actinomycin, chloramphemcol and tetracyclme
  • SP1 , SP2, SP3, SP4 or SP5 A variety of host cells can be used for the production of SP1 , SP2, SP3, SP4 or SP5 including bacterial, fungal, mammalian and insects cells
  • General transformation procedures are taught in Current Protocols In Molecular Biology (vol 1 , edited by Ausubel et al , John Wiley & Sons, Inc 1987, Chapter 9) and include calcium phosphate methods, transformation using DEAE-Dextran and electroporation Plant transformation methods are taught in Rodnquez (WO 95/14099, published 26 May 1995)
  • the host cell is a gram-positive microorganism and in another preferred embodiment, the host cell is Bacillus
  • nucleic acid encoding one or more serine protease(s) of the present invention is introduced into a host cell via an expression vector capable of replicating within the host cell Suitable replicating plasmids for Bacillus are described in Molecular Biological Methods for Bacillus, Ed Harwood and Cutting, John Wiley & Sons, 1990, hereby expressly incorporated by reference, see chapter 3 on plasmids Suitable replicating plasmids for B subtilis are listed on page 92
  • nucleic acid encoding a serine protease(s) of the present invention is stably integrated into the microorganism genome
  • Preferred host cells are gram-positive host cells
  • Bacillus Another preferred host is Bacillus subtilis
  • Several strategies have been described in the literature for the direct cloning of DNA in Bacillus Plasmid marker rescue transformation involves the uptake of a donor plasmid by competent cells carrying a partially homologous resident plasmid (Contente et al , Plasmid 2 555-571 (1979), Haima et al , Mol Gen Genet 223 185-191 (1990), We rauch et al , J Bactenol 154(3) 1077-1087 (1983), and Weinrauch et al , J Bactenol 169(3) 1205-1211 (1987))
  • the incoming donor plasmid recombines with the homologous region of the resident "helper" plasmid in a process that mimics chromosomal
  • a host cell has been transformed with a mutated or a naturally occurring gene encoding a gram-positive SP1 , SP2, SP3, SP4 or SP5 detection of the presence/absence of marker gene expression can suggests whether the gene of interest is present However, its expression should be confirmed
  • the nucleic acid encoding a serine protease is inserted within a marker gene sequence
  • recombinant cells containing the insert can be identified by the absence of marker gene function
  • a marker gene can be placed in tandem with nucleic acid encoding the serine protease under the control of a single promoter
  • Expression of the marker gene in response to induction or selection usually indicates expression of the serine protease as well
  • host cells which contain the coding sequence for a senne protease and express the protein may be identified by a variety of procedures known to those of skill in the art These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridization and protein bioassay or immunoassay techniques which
  • cysteine polynucleotide sequence can be detected by DNA- DNA or DNA-RNA hybridization or amplification using probes, portions or fragments of B subtilis SP1 , SP2, SP3, SP4 or SP5
  • Means for determining the levels of secretion of a heterologous or homologous protein in a gram-positive host cell and detecting secreted proteins include, using either polyclonal or monoclonal antibodies specific for the protein Examples include enzyme- linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS) These and other assays are described, among other places, in Hampton R et al (1990, Serological Methods, a Laboratory Manual. APS Press, St Paul MN) and Maddox DE et al (1983, J Exp Med 158 1211)
  • RNA polymerase such as T7, T3 or SP6 and labeled nucleotides
  • reporter molecules or labels include those radionuc des, enzymes, fluorescent, chemiluminescent or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and the like
  • Patents teaching the use of such labels include US Patents 3,817,837, 3,850,752, 3,939,350, 3,996,345, 4,277,437, 4,275,149 and 4,366,241
  • recombinant immunoglobulms may be produced as shown in US Patent No 4,816,567 and incorporated herein by reference
  • Gram positive host cells transformed with polynucleotide sequences encoding heterologous or homologous protein may be cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture
  • the protein produced by a recombinant gram-positive host cell comprising a serine protease of the present invention will be secreted into the culture media
  • Other recombinant constructions may join the heterologous or homologous polynucleotide sequences to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins (Kroll DJ et al (1993) DNA Cell Biol 12 441-53)
  • Such purification facilitating domains include, but are not limited to, metal chelatmg peptides such as histidine-tryptophan modules that allow purification on immobilized metals (Porath J (1992) Protein Expr Pu ⁇ f 3 263-281), protein A domains that allow purification on immobilized immunoglobuhn, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle WA)
  • a cleavable linker sequence such as Factor XA or enterokinase (Invitrogen, San Diego CA) between the purification domain and the heterologous protein can be used to facilitate purification
  • the present invention provides genetically engineered host cells comprising preferably non-revertable mutations or deletions in the naturally occurring gene encoding one or more of SP1 , SP2, SP3, SP4 or SP5 such that the proteolytic activity is diminished or deleted altogether
  • the host cell may contain additional protease deletions, such as deletions of the mature subtihsn protease and/or mature neutral protease disclosed in United States Patent No 5,264,366
  • the host cell is genetically engineered to produce a desired protein or polypeptide
  • the host cell is a Bacillus
  • the host cell is a Bacillus subtilis
  • a host cell is genetically engineered to produce a gram-positive SP1 , SP2, SP3, SP4 or SP5
  • the host cell is grown under large scale fermentation conditions, the SP1 , SP2, SP3, SP4 or SP5 is isolated and/or purified and used in cleaning compositions such as detergents WO 95/10615 discloses detergent formulation
  • a serine protease of the present invention can be useful in formulating various cleaning compositions
  • a number of known compounds are suitable surfactants useful in compositions comprising the serine protease of the invention These include nonionic, anionic, cationic, anionic or zwitte ⁇ onic detergents, as disclosed in US 4,404,128 and US 4,261 ,868
  • a suitable detergent formulation is that described in Example 7 of US Patent 5,204,015
  • the art is familiar with the different formulations which can be used as cleaning compositions
  • a serine protease of the present invention can be used, for example, in bar or liquid soap applications, dishcare formulations, contact lens
  • a serine protease of the present invention can be formulated into known powdered and liquid detergents having pH between 6 5 and 12.0 at levels of about .01 to about 5% (preferably .1 % to .5%) by weight
  • These detergent cleaning compositions can also include other enzymes such as known proteases, amylases, cellulases, lipases or endoglycosidases, as well as builders and stabilizers
  • a serine protease of the present invention can be used in a cleaning composition without detergents, again either alone or in combination with builders and stabilizers.
  • compositions for the treatment of a textile that includes a serine protease of the present invention.
  • the composition can be used to treat for example silk or wool as described in publications such as RD 216,034, EP 134,267, US 4,533,359; and EP 344,259
  • Proteases can be included in animal feed such as part of animal feed additives as described in, for example, US 5,612,055, US 5,314,692, and US 5,147,642
  • a B.subt s SP1 , SP2, SP3, SP4 or SP5 polynucleotide, or any part thereof, provides the basis for detecting the presence of gram-positive microorganism polynucleotide homologs through hybridization techniques and PCR technology
  • one aspect of the present invention is to provide for nucleic acid hybridization and PCR probes which can be used to detect polynucleotide sequences, including genomic and cDNA sequences, encoding gram-positive SP1 , SP2, SP3, SP4 or SP5 or portions thereof.
  • Genomic DNA from Bacillus cells is prepared as taught in Current Protocols In Molecular Biology vol 1 , edited by Ausubel et al , John Wiley & Sons, Inc 1987, chapter 2 4 1 Generally, Bacillus cells from a saturated liquid culture are lysed and the proteins removed by digestion with protemase K Cell wall debris, polysaccha ⁇ des, and remaining proteins are removed by selective precipitation with CTAB, and high molecular weight genomic DNA is recovered from the resulting supernatant by isopropanol precipitation If exceptionally clean genomic DNA is desired, an additional step of purifying the Bacillus genomic DNA on a cesium chloride gradient is added
  • the partially digested Bacillus genomic DNA is subjected to size fractionation on a 1% agarose gel prior to cloning into a vector Alternatively, size fractionation on a sucrose gradient can be used.
  • the genomic DNA obtained from the size fractionation step is purified away from the agarose and ligated into a cloning vector appropriate for use in a host cell and transformed into the host cell
  • DNA derived from a gram-positive microorganism is prepared according to the methods disclosed in Current Protocols in Molecular Biology, Chap 2 or 3
  • the nucleic acid is subjected to hybridization and/or PCR amplification with a probe or primer derived from SP1
  • a preferred probe comprises the nucleic acid section encoding conserved ammo acid residues
  • the nucleic acid probe is labeled by combining 50 pmol of the nucleic acid and 250 mCi of [gamma ⁇ 2 P] adenosme t ⁇ phosphate (Amersham Chicago IL) and T4 polynucleotide kmase (DuPont NEN®, Boston MA)
  • the labeled probe is purified with Sephadex G-25 super fine resin column (Pharmacia)
  • a portion containing 10/ counts per minute of each is used in a typical membrane based hybridization analysis of nucleic acid sample of either genomic or cDNA origin
  • the DNA sample which has been subjected to restriction endonuclease digestion is fractionated on a 0.7 percent agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH).
  • Hybridization is carried out for 16 hours at 40 degrees C.
  • blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate.
  • the blots are exposed to film for several hours, the film developed and hybridization patterns are compared visually to detect polynucleotide homologs of B. subtilis SP1.
  • the homologs are subjected to confirmatory nucleic acid sequencing. Methods for nucleic acid sequencing are well known in the art.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Detergent Compositions (AREA)
EP98935681A 1997-07-15 1998-07-14 Proteases from gram-positive organisms Ceased EP0991754A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP98935681A EP0991754A2 (en) 1997-07-15 1998-07-14 Proteases from gram-positive organisms

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97305232 1997-07-15
EP97305232 1997-07-15
EP98935681A EP0991754A2 (en) 1997-07-15 1998-07-14 Proteases from gram-positive organisms
PCT/US1998/014647 WO1999003984A2 (en) 1997-07-15 1998-07-14 Proteases from gram-positive organisms

Publications (1)

Publication Number Publication Date
EP0991754A2 true EP0991754A2 (en) 2000-04-12

Family

ID=8229415

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98935681A Ceased EP0991754A2 (en) 1997-07-15 1998-07-14 Proteases from gram-positive organisms

Country Status (4)

Country Link
EP (1) EP0991754A2 (ja)
JP (1) JP2001510037A (ja)
AU (1) AU8487098A (ja)
WO (1) WO1999003984A2 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9724629D0 (en) * 1997-11-20 1998-01-21 Genencor Int Bv Alpha/beta hydrolase-fold enzymes
DK2339016T3 (da) 2002-03-29 2017-01-23 Danisco Us Inc Øget produktion af subtilisiner
US8288136B2 (en) 2005-12-13 2012-10-16 E. I. Du Pont De Nemours And Company Production of peracids using an enzyme having perhydrolysis activity
US7964378B2 (en) 2005-12-13 2011-06-21 E.I. Du Pont De Nemours And Company Production of peracids using an enzyme having perhydrolysis activity
US7951566B2 (en) 2005-12-13 2011-05-31 E.I. Du Pont De Nemours And Company Production of peracids using an enzyme having perhydrolysis activity
US8518675B2 (en) 2005-12-13 2013-08-27 E. I. Du Pont De Nemours And Company Production of peracids using an enzyme having perhydrolysis activity
US7723083B2 (en) 2005-12-13 2010-05-25 E.I. Du Pont De Nemours And Company Production of peracids using an enzyme having perhydrolysis activity
EP2331686B1 (en) 2008-08-13 2012-05-09 E. I. du Pont de Nemours and Company Control of enzymatic peracid generation
US8105810B2 (en) 2008-10-03 2012-01-31 E. I. Du Pont De Nemours And Company Method for producing peroxycarboxylic acid
AU2010281409B2 (en) 2009-07-27 2014-08-14 The Chemours Company Fc, Llc Enzymatic in situ preparation of peracid-based removable antimicrobial coating compositions and methods of use
US8222012B2 (en) 2009-10-01 2012-07-17 E. I. Du Pont De Nemours And Company Perhydrolase for enzymatic peracid production
CN102952787B (zh) * 2012-10-22 2014-07-16 南京工业大学 一种乙酰木聚糖酯酶及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003078A1 (en) * 1988-11-18 1990-05-18 Alan Sloma Protease deletion

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9903984A2 *

Also Published As

Publication number Publication date
WO1999003984A2 (en) 1999-01-28
WO1999003984A3 (en) 1999-04-08
JP2001510037A (ja) 2001-07-31
AU8487098A (en) 1999-02-10

Similar Documents

Publication Publication Date Title
EP1042490A2 (en) Proteases from gram positive organisms
WO1999014342A1 (en) Proteases from gram-positive organisms
EP1042487A2 (en) Proteases from gram positive organisms
WO1999003984A2 (en) Proteases from gram-positive organisms
US7220716B2 (en) Proteases from gram-positive organisms
US8101563B2 (en) Proteases from gram-positive organisms
US6911333B2 (en) Proteases from gram-positive organisms
US7070819B2 (en) Proteases from gram positive organisms
US6872807B2 (en) Proteases from gram positive organisms
US6762039B2 (en) Bacillus subtillis with an inactivated cysteine protease-1
US7078216B2 (en) Proteases from gram positive organisms
US7033817B2 (en) Proteases from gram positive organisms
WO1999034002A2 (en) Proteases from gram positive organisms
EP0998571A2 (en) Proteases from gram-positive organisms
EP1042488A2 (en) Proteases from gram positive organisms

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000204

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GENENCOR INTERNATIONAL, INC.

17Q First examination report despatched

Effective date: 20030509

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20051127